All In Biotech

Drug Trial Radar · NCT05877963

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Jun 13, 2023

Primary completion

Jan 21, 2027

Study completion Jan 21, 2027

Sponsor

Lead sponsor
TG Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • UblituximabBiological

    Administered as an intravenous (IV) infusion.

  • PlaceboDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48Time frame: Baseline up to Week 48
  2. Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of UblituximabTime frame: Predose and at multiple timepoints up to Week 16

Locations

51 sites in 2 countries. Site status is shown where the registry gives one.

  • TG Therapeutics Investigational Trial Site

    Birmingham, Alabama · Recruiting

  • TG Therapeutics Investigational Trial Site

    Cullman, Alabama · Recruiting

  • TG Therapeutics Investigational Trial Site

    Orange, California · Recruiting

  • TG Investigational Site

    Fort Collins, Colorado · Recruiting

  • TG Therapeutics Investigational Trial Site

    Washington D.C., District of Columbia · Recruiting

  • TG Therapeutics Investigational Trial Site

    Tampa, Florida · Recruiting

  • TG Therapeutics Investigational Trial Site

    Atlanta, Georgia · Recruiting

  • TG Therapeutics Investigational Trial Site

    Atlanta, Georgia · Recruiting

  • TG Therapeutics Investigational Trial Site

    Savannah, Georgia · Recruiting

  • TG Therapeutics Investigational Trial Site

    Chicago, Illinois · Recruiting

  • TG Therapeutics Investigational Trial Site

    Indianapolis, Indiana · Recruiting

  • TG Therapeutics Investigational Trial Site

    Iowa City, Iowa · Recruiting

  • TG Therapeutics Investigational Trial Site

    Overland Park, Kansas · Recruiting

  • TG Therapeutics Investigational Trial Site

    Overland Park, Kansas · Completed

  • TG Therapeutics Investigational Trial Site

    Lutherville, Maryland · Recruiting

  • TG Therapeutics Investigational Trial Site

    Boston, Massachusetts · Recruiting

  • TG Therapeutics Investigational Trial Site

    Boston, Massachusetts · Recruiting

  • TG Therapeutics Investigational Trial Site

    Foxborough, Massachusetts · Recruiting

  • TG Therapeutics Investigational Trial Site

    North Worcester, Massachusetts · Recruiting

  • TG Therapeutics Investigational Trial Site

    Wellesley, Massachusetts · Recruiting

  • TG Investigational Site

    Farmington, Michigan · Recruiting

  • TG Therapeutics Investigational Trial Site

    Golden Valley, Minnesota · Recruiting

  • TG Therapeutics Investigational Trial Site

    Plymouth, Minnesota · Recruiting

  • TG Therapeutics Investigational Trial Site

    St Louis, Missouri · Recruiting

  • TG Therapeutics Investigational Trial Site

    New York, New York · Recruiting

  • TG Therapeutics Investigational Trial Site

    New York, New York · Recruiting

  • TG Therapeutics Investigational Trial SiteCharlotte

    Charlotte, North Carolina · Recruiting

  • TG Therapeutics Investigational Trial Site

    Raleigh, North Carolina · Recruiting

  • TG Therapeutics Investigational Trial Site

    Cincinnati, Ohio · Recruiting

  • TG Therapeutics Investigational Trial Site

    Cleveland, Ohio · Recruiting

  • TG Therapeutics Investigational Trial Site

    Dayton, Ohio · Recruiting

  • TG Therapeutics Investigational Trial Site

    Oklahoma City, Oklahoma · Recruiting

  • TG Therapeutics Investigational Trial Site

    Greenville, South Carolina · Recruiting

  • TG Therapeutics Investigational Trial Site

    Knoxville, Tennessee · Recruiting

  • TG Therapeutics Investigational Trial Site

    Houston, Texas · Completed

  • TG Therapeutics Investigational Trial Site

    Salt Lake City, Utah · Recruiting

  • TG Therapeutics Investigational Trial Site

    Vienna, Virginia · Recruiting

  • TG Therapeutics Investigational Trial Site

    Kirkland, Washington · Recruiting

  • TG Therapeutics Investigational Trial Site

    Seattle, Washington · Recruiting

  • TG Therapeutics Investigational Trial Site

    Spokane, Washington · Recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.